Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the…
Parkinson’s disease (PD) is predominantly recognized as a motor disorder, but PD is also associated with a diverse mix of disabling nonmotor symptoms, including cognitive impairment and dementia…
The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer / Eli Lilly’s tanezumab and Regeneron / Teva / Mitsubishi Tanabe…
The management of pediatric patients with moderate to severe atopic dermatitis (AD) is poised for transformation. Sanofi/Regeneron’s Dupixent, on the heels of a positive Phase III study in…
Drug treatment of glaucoma focuses on reducing / controlling IOP and preserving visual function. Given the availability of therapies from several drug classes (e.g., PGAs, beta blockers, FDCs),…